Quell Therapeutics Ltd.. (1/6/22). "Press Release: Quell Therapeutics Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference". London & Boston, MA.

	Organisation	Quell Therapeutics Ltd. (QuellTX)
	Organisation 2	Stern Investor Relations Inc. (Stern IR)
	Group	Precision Medicine Group (Group)
	Product	J.P. Morgan 40th Annual Healthcare Conference 2022 DIGITAL
	Product 2	regulatory T cell therapy (Tregs)
	Person	Swallow, Mark (Huntsworth 201101 Citigate Dewe Rogerson London Senior Director Life Sciences)

Quell Therapeutics Ltd (“Quell”), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that management will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference, being held virtually, on Tuesday, January 11, 2022 at 12:00 pm ET.

About Quell Therapeutics

Quell Therapeutics is the world leader in developing engineered T-regulatory (Treg) cell therapies that aim to harness, direct and optimize their immune suppressive properties to address serious medical conditions driven by the immune system.

The Company is leveraging its pioneering phenotype lock technology, unique multi-modular platform and integrated manufacturing capabilities to design and develop a pipeline of highly engineered Treg cell therapies with greater potential for stability, persistence and potency than earlier generations of Treg cell therapy approaches.

Quell’s lead candidate QEL-001 is being developed to induce operational tolerance following liver transplantation, with the potential to protect the post-transplant liver without the need for chronic immunosuppressive medications. Quell is also advancing additional programs in neuroinflammatory and autoimmune diseases. www.quell-tx.com.

Contacts

Luke Henry, Chief Business Officer
Quell Therapeutics
IR@quell-tx.com

Media: Mark Swallow, Frazer Hall, Eleanor Perkin
MEDiSTRAVA Consulting
+44 203 928 6900
Quell-Tx@Medistrava.com

Investors: Christina Tartaglia
Stern Investor Relations, Inc.
+1 212 362 1200
christina@sternir.com

Record changed: 2022-04-27